- Home
- PRPL vs CTMX Comparison
PRPL vs CTMX Comparison
Compare PRPL & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- CTMX
- Stock Information
- Founded
- PRPL 2010
- CTMX 2008
- Country
- PRPL United States
- CTMX United States
- Employees
- PRPL N/A
- CTMX N/A
- Industry
- PRPL Home Furnishings
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- PRPL Consumer Discretionary
- CTMX Health Care
- Exchange
- PRPL Nasdaq
- CTMX Nasdaq
- Market Cap
- PRPL 90.3M
- CTMX 85.3M
- IPO Year
- PRPL N/A
- CTMX 2015
- Fundamental
- Price
- PRPL $1.01
- CTMX $0.87
- Analyst Decision
- PRPL Buy
- CTMX Buy
- Analyst Count
- PRPL 4
- CTMX 6
- Target Price
- PRPL $2.53
- CTMX $5.77
- AVG Volume (30 Days)
- PRPL 414.7K
- CTMX 1.2M
- Earning Date
- PRPL 03-11-2025
- CTMX 03-10-2025
- Dividend Yield
- PRPL N/A
- CTMX N/A
- EPS Growth
- PRPL N/A
- CTMX N/A
- EPS
- PRPL N/A
- CTMX 0.16
- Revenue
- PRPL $504,838,000.00
- CTMX $126,617,000.00
- Revenue This Year
- PRPL N/A
- CTMX $22.55
- Revenue Next Year
- PRPL $1.89
- CTMX N/A
- P/E Ratio
- PRPL N/A
- CTMX $5.42
- Revenue Growth
- PRPL N/A
- CTMX 33.66
- 52 Week Low
- PRPL $0.75
- CTMX $0.79
- 52 Week High
- PRPL $2.33
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- PRPL 64.41
- CTMX 37.85
- Support Level
- PRPL $0.91
- CTMX $0.79
- Resistance Level
- PRPL $1.03
- CTMX $1.17
- Average True Range (ATR)
- PRPL 0.08
- CTMX 0.08
- MACD
- PRPL 0.02
- CTMX -0.02
- Stochastic Oscillator
- PRPL 92.88
- CTMX 21.37
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.